GlassScriptPhysician profile
Michael Thomas Hames
NPI 1811058258
$100,054.20
in general payments reported to CMS, 2019-2025
15 companies · $99K in 2025
The $99K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.84 · 2020: $72.33 · 2021: $145 · 2022: $245 · 2023: $396 · 2024: $481 · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $98K · Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $98,200.00 |
| Food and Beverage | $1,376.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $98,242.53 | 2023-2025 | |
| Stryker Corporation | $641.10 | 2023-2025 | Ortholoc 2 Lapifuse, Ortholoc 3di, Variax |
| Paratek Pharmaceuticals, INC. | $491.27 | 2020-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $153.44 | 2021-2023 | Orbactiv, Kimyrsa |
| Kowa Pharmaceuticals America, INC. | $140.38 | 2022 | |
| Organogenesis INC. | $130.34 | 2019-2024 | |
| Abbvie INC. | $108.04 | 2021-2025 | |
| Horizon Therapeutics Plc | $31.69 | 2021 | |
| Medtronic, INC. | $23.31 | 2024 | Intellis Adaptivestim |
| Vertex Pharmaceuticals Incorporated | $19.91 | 2025 | |
| Hartmann USA, INC. | $17.54 | 2021 | |
| Orthofix Medical, INC. | $15.89 | 2020 | |
| Ibsa Pharma INC. | $14.17 | 2024 | Licart, Tirosint |
| Smith+Nephew, INC. | $13.22 | 2023 | Renasys Go V2 Home |
| Zyla Life Sciences, INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.